| AASLD

Home

GENETIC ABLATION OF CD4 T CELLS IN MICE ATTENUATES LIVER INJURY, INFLAMMATION, AND FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS

Read more about GENETIC ABLATION OF CD4 T CELLS IN MICE ATTENUATES LIVER INJURY, INFLAMMATION, AND FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS

<div>Background: Nonalcoholic steatohepatitis (NASH) is a progressive condition characterized by excessive inflammation, which may lead to fibrosis. To date, the contribution of T cells to NASH remains largely unexplored. Our unpublished data suggest that CD4 T cells with pathogenic Th1 phenotype accumulate in murine NASH livers. Therefore, we investigated the role of CD4 T lymphocytes in NASH development.

SINGLE-CELL ANALYSIS OF LIVER FINE NEEDLE ASPIRATES REVEALS DIFFERENCES IN GENE EXPRESSION BETWEEN CHRONIC HBV-MONOINFECTED VERSUS HBV/HIV-COINFECTED ADULTS

Read more about SINGLE-CELL ANALYSIS OF LIVER FINE NEEDLE ASPIRATES REVEALS DIFFERENCES IN GENE EXPRESSION BETWEEN CHRONIC HBV-MONOINFECTED VERSUS HBV/HIV-COINFECTED ADULTS

<div>Background: HIV infection accelerates the natural history of HBV-related liver disease. The mechanisms by which this occurs are incompletely understood due to limited access to comparable groups of people living with HBV with/without HIV and lack of access to the liver compartment.

SIMULTANEOUS LIVER TRANSPLANT AND SLEEVE GASTRECTOMY IS A SAFE SURGICAL OPTION THAT IMPROVES METABOLIC SYNDROME AND REDUCES ALLOGRAFT STEATOSIS

Read more about SIMULTANEOUS LIVER TRANSPLANT AND SLEEVE GASTRECTOMY IS A SAFE SURGICAL OPTION THAT IMPROVES METABOLIC SYNDROME AND REDUCES ALLOGRAFT STEATOSIS

<div>Background: The prevalence of obesity and metabolic syndrome (MS) is rising dramatically among liver transplant (LT) candidates, many of whom have NASH. Following LT, untreated MS often causes recurrent NAFLD and NASH. Several small case series describe bariatric surgery pre-, post-, or concurrently with LT as a treatment for MS. We reviewed our experience with LT and concurrent sleeve gastrectomy (LTSG) with aims to determine long-term safety, efficacy, and impact on progression of MS and liver disease after transplantation.

LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)– A REAL-WORLD NATIONWIDE U.S. STUDY

Read more about LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)– A REAL-WORLD NATIONWIDE U.S. STUDY

<div>Background: All-oral interferon-free direct-acting antiviral agents (DAAs) for treatment and cure of hepatitis C virus (HCV) became available in 2013-2014. Our primary objective is to determine the proportion of patients with HCV-related HCC who received DAA after 2014 and factors associated with treatment receipt. We also evaluated DAA treatment impact on the overall survival in this population as a secondary outcome.

NEGATIVE IMPACT OF PNPLA3 rs738409 C>G IS SIGNIFICANTLY MODIFIED BY DIETARY FACTORS, CAFFEINE AND NON-HEAVY ALCOHOL CONSUMPTION IN THE US POPULATION

Read more about NEGATIVE IMPACT OF PNPLA3 rs738409 C>G IS SIGNIFICANTLY MODIFIED BY DIETARY FACTORS, CAFFEINE AND NON-HEAVY ALCOHOL CONSUMPTION IN THE US POPULATION

<div>Background: PNPLA3 rs738409 C>G is strongly associated with NAFLD and its severity. PNPLA3 expression is highly regulated by changes in energy balance; however, little is known about the interplay between PNPLA3, dietary factors, alcohol intake, and risk of liver-related death (LRD).

HIGH DOSES OF ALBUMIN INCREASES MORTALITY AND COMPLICATIONS IN TERLIPRESSIN TREATED PATIENTS WITH CIRRHOSIS: INSIGHTS FROM THE ATTIRE TRIAL

Read more about HIGH DOSES OF ALBUMIN INCREASES MORTALITY AND COMPLICATIONS IN TERLIPRESSIN TREATED PATIENTS WITH CIRRHOSIS: INSIGHTS FROM THE ATTIRE TRIAL

<div>Background: The CONFIRM trial revealed potential harm with terlipressin in a subset of patients, who developed respiratory failure. It remains unclear to what degree concomitant albumin contributes to the undesirable outcomes of terlipressin treatment. Using ATTIRE trial data, we compared safety of serum targeted albumin infusions to standard-of-care in patients with cirrhosis receiving terlipressin.

AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE

Read more about AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE

<div>Background: This study extends the follow-up of participants who completed a randomized placebo-controlled trial evaluating the safety and efficacy of tenofovir disoproxil fumarate (TDF) in reducing the risk of histological progression in patients with chronic hepatitis B (CHB) characterized by high viral load and minimally raised serum alanine aminotransferase (ALT) levels. We report herein the outcomes of patients who received three years of open-label TDF treatment after completing a randomized trial

HEAR-MHE: POINT-OF-CARE ANALYSIS OF RECORDED SPEECH AS A NOVEL METHOD TO DETECT HEPATIC ENCEPHALOPATHY

Read more about HEAR-MHE: POINT-OF-CARE ANALYSIS OF RECORDED SPEECH AS A NOVEL METHOD TO DETECT HEPATIC ENCEPHALOPATHY

<div>Background: Variation in speech may be an early sign of minimal hepatic encephalopathy (MHE) or future overt HE (OHE). Though a battery of tests is available for MHE assessment, these are cumbersome and rarely used in clinical practice. In a prospective study, we evaluated the ability of speech recorded at home or in the office to correlate with validated HE assessments in patients of diverse backgrounds.

HEPATIC LOBULAR INFLAMMATION IS THE MOST IMPACTED PROGNOSTIC FACTOR RATHER THAN FIBROSIS IN PATIENTS WITH BIOPSY-PROVEN MASLD: MULTI-CENTER STUDY

Read more about HEPATIC LOBULAR INFLAMMATION IS THE MOST IMPACTED PROGNOSTIC FACTOR RATHER THAN FIBROSIS IN PATIENTS WITH BIOPSY-PROVEN MASLD: MULTI-CENTER STUDY

<div>Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) captures patients at high risk of hepatic fibrosis and cardiovascular disease. However, limited information is available on the prognosis of MASLD. This study aimed to investigate the prognosis of patients with biopsy-proven MASLD and validate a group of fatty liver patients excluded from MASLD because of no metabolic abnormalities by a multi-center longitudinal cohort.

PSMP INHIBITS HCC PROGRESSION BY REGULATING THE POLARIZATION OF TUMOR-ASSOCIATED MACROPHAGES THROUGH THE PI3K/AKT PATHWAY

Read more about PSMP INHIBITS HCC PROGRESSION BY REGULATING THE POLARIZATION OF TUMOR-ASSOCIATED MACROPHAGES THROUGH THE PI3K/AKT PATHWAY

<div>Background: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and represents a major global health-care challenge. PC3 secreted microprotein (PSMP) is a novel chemotactic cytokine that can recruit peripheral blood monocytes and lymphocytes through its chemokine receptor CCR2. Our previous study found that PSMP is significantly highly expressed in human and mouse liver fibrosis/cirrhosis.

Subscribe to